Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.
Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, Mogenet A, Bresson JL, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert EB, Albert PS, Albert ML. Bisiaux A, et al. Among authors: sadorge c. J Urol. 2009 Apr;181(4):1571-80. doi: 10.1016/j.juro.2008.11.124. Epub 2009 Feb 23. J Urol. 2009. PMID: 19230924
Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers.
Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, Johnson J, Liddy H, Cosgrove CA, Allavena P, Mantovani A, Béchet S, Fontaine-Thompson A, Griffin GE, Dupont F, Sansonetti PJ, Lewis DJ. Sadorge C, et al. Vaccine. 2008 Feb 13;26(7):978-87. doi: 10.1016/j.vaccine.2007.11.024. Epub 2007 Dec 3. Vaccine. 2008. PMID: 18207287 Clinical Trial.
Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML. Launay O, et al. Among authors: sadorge c. Vaccine. 2009 Feb 18;27(8):1184-91. doi: 10.1016/j.vaccine.2008.12.021. Epub 2009 Jan 9. Vaccine. 2009. PMID: 19135496 Clinical Trial.
In a preliminary Phase 1 single dose prospective study, we showed that SC599 vaccine was well tolerated, and the maximum tolerable dose was greater than 10(8) CFU [Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, et al. Phase 1 clinical trial of live a …
In a preliminary Phase 1 single dose prospective study, we showed that SC599 vaccine was well tolerated, and the maximum tolerable dose was …
Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C. Diez-Domingo J, et al. Among authors: sadorge c. Vaccine. 2015 Feb 4;33(6):789-95. doi: 10.1016/j.vaccine.2014.12.024. Epub 2014 Dec 30. Vaccine. 2015. PMID: 25555381 Free article. Clinical Trial.
Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
Gajdos V, Vidor E, Richard P, Tran C, Sadorge C. Gajdos V, et al. Among authors: sadorge c. Vaccine. 2015 Jul 31;33(32):3988-96. doi: 10.1016/j.vaccine.2015.06.036. Epub 2015 Jun 15. Vaccine. 2015. PMID: 26087294
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.
Laurichesse H, Zimmermann U, Galtier F, Launay O, Duval X, Richard P, Sadorge C, Soubeyrand B. Laurichesse H, et al. Among authors: sadorge c. Hum Vaccin Immunother. 2012 Dec 1;8(12):1875-81. doi: 10.4161/hv.22083. Epub 2012 Oct 2. Hum Vaccin Immunother. 2012. PMID: 23032160 Free PMC article. Clinical Trial.
Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series.
Oliver JL, Sadorge C, Boisnard F, Snape MD, Tomlinson R, Mann R, Rudd P, Bhakthavalsala S, Faust SN, Heath PT, Hughes SM, Borrow R, Thomas S, Finn A. Oliver JL, et al. Among authors: sadorge c. Vaccine. 2020 Jul 31;38(35):5718-5725. doi: 10.1016/j.vaccine.2020.06.015. Epub 2020 Jul 10. Vaccine. 2020. PMID: 32654902 Clinical Trial.
A reliable diagnosis of human rabies based on analysis of skin biopsy specimens.
Dacheux L, Reynes JM, Buchy P, Sivuth O, Diop BM, Rousset D, Rathat C, Jolly N, Dufourcq JB, Nareth C, Diop S, Iehlé C, Rajerison R, Sadorge C, Bourhy H. Dacheux L, et al. Among authors: sadorge c. Clin Infect Dis. 2008 Dec 1;47(11):1410-7. doi: 10.1086/592969. Clin Infect Dis. 2008. PMID: 18937576
14 results